China pharmaceutical contract manufacturing market & Forecast to 2023

Posted by pranshu@95 on August 6th, 2019

Orion Market Research (OMR) recently published a market research report on China pharmaceutical contract manufacturing market. According to OMR analysis, China pharmaceutical contract manufacturing market is estimated to rise with a significant CAGR during the forecast period (2018-2023). The major factors that are contributing to the growth of China pharmaceutical contract manufacturing market includes the shift of global pharmaceutical firms for outsourcing in China and the increasing burden of non-communicable diseases, such as CVD (Cardiovascular disease) and cancer. According to the American Cancer Society, in 2015, China witnessed around 4.3 million new cancer incidences and over 2.8 million cancer fatalities. Similarly, the prevalence of CVD is rising in the country. Such an increasing prevalence of CVD and cancer in China is encouraging contract pharma companies to develop new drugs in the country.

A full report of China pharmaceutical contract manufacturing market is available at:

https://www.omrglobal.com/industry-reports/china-pharmaceutical-contract-manufacturing-market/

Furthermore, China pharmaceutical contract manufacturing market is segmented on the basis of process type, product type, route of administration, and service. The report provides detailed & insightful chapters which include market overview, key findings, strategic recommendations, market estimations, market determinants, key company analysis, market insights, company profiling, market segmentation, geographical analysis, analyst insights and predictive analysis of the market.

Market Segmentation

1. China Pharmaceutical Contract Manufacturing Market by Manufacturing Process Type

• Sterile Manufacturing
• Non-Sterile Manufacturing

2. China Pharmaceutical Contract Manufacturing Market by Product Type

• Over-The-Counter (OTC) Drugs
• Active Pharmaceutical Ingredients (API)
• Finished Dosage Formulation
  • Solid Dose
  • Liquid Dose
  • Injectable Dose
• Others (Nutritional Products and Packaging)

3. China Pharmaceutical Contract Manufacturing Market by Route of Administration

• Oral Administration
• Inhaled Administration
• Parenteral Administration
• Others (Rectal and Vaginal)

4. China Pharmaceutical Contract Manufacturing Market by Service

• R&D
• Manufacturing
• Non-Clinical Service such as Supply Chain Management

Company Profile

• Agno Pharma
• B. Braun Melsungen AG
• Bayer AG
• Boehringer Ingelheim International GmbH
• Canagen Pharmaceuticals Inc.
• Catalent Pharma Solutions, Inc.
• China Chemical & Pharmaceutical Co., Ltd.
• Dishman Group
• Evonik Industries AG
• Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd.
• GlaxoSmithKline PLC
• Hangzhou VIWA Co., Ltd.
• Ingredient China Group Ltd.
• Mercator Pharma
• Merck & Co., Inc.
• Novozymes A/S
• Pfizer Inc.
• Shandong Xinhua Pharmaceutical Co., Ltd.
• Shanghai Fosun Pharmaceutical Co., Ltd.
• Sigfried Holding AG
• Sirio Pharma Co., Ltd.
• STA Pharmaceutical Co., Ltd.
• West Pharmaceutical Services, Inc.
• WuXiAppTec Group
• Wuxi Griffin Pharmaceutical Co., Ltd.
• Zhejiang Hisun Pharmaceutical Co. Ltd.
• Zhejiang Jingxin Pharmaceutical Co., Ltd.

The key objectives of the China pharmaceutical contract manufacturing market study:

• To analyze the China pharmaceutical contract manufacturing market by segments with historical data of 2017 and 2018 and forecast to 2025.
• To study the key factors influencing the growth of the market.
• Focuses on the key leaders to define and analyze the sales volume, value, share, competitive landscapes, SWOT analysis, and development plans.
• To analyze the China pharmaceutical contract manufacturing market growth, global trends, future prospectus and contribution to the market.

Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667,+91 780-304-0404